Lilly's Cyramza misses liver-cancer target

Share this article:

Eli Lilly's gastric cancer drug Cyramza, previously known as ramucirumab, failed to hit its Phase-III targets among liver-cancer patients using the drug as a second-line treatment. The Wall Street Journal reports that although Cyramza patients had more favorable overall survival rates than placebo patients, the differences were not statistically significant.

The drug failed to hit targets in a breast cancer clinical trial last year, but showed promise in Phase-III tests among non-small cell lung cancer patients when used with docetaxel.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters